Literature DB >> 11438912

Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.

J W Kim1, H S Lee, G H Woo, J H Yoon, J J Jang, J G Chi, C Y Kim.   

Abstract

We present a case of infection with lamivudine-resistant mutant hepatitis B virus (HBV) that fatally exacerbated hepatitis following the emergence of HBV with mutations in the tyrosine-methionine-aspartate-aspartate (YMDD) motif in an immunocompetent patient who was receiving long-term lamivudine therapy. Restriction fragment length polymorphism analysis showed that the YMDD-motif mutant was the predominant form of circulating HBV at the time of the fatal exacerbation, and a necropsy specimen of the liver revealed submassive hepatic necrosis without steatosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438912     DOI: 10.1086/321879

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

1.  Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure.

Authors:  D Thabut; V Ratziu; B Bernard-Chabert; T Poynard; Y Benhamou; V Thibault
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

Review 2.  Resistance to lamivudine therapy: is there more than meets the eye?

Authors:  G Dusheiko; A Bertoletti
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

3.  Synergistic effect of a novel oxymatrine-baicalin combination against hepatitis B virus replication, alpha smooth muscle actin expression and type I collagen synthesis in vitro.

Authors:  Yang Cheng; Jian Ping; Huai-Dong Xu; Hai-Jun Fu; Zhao-Hui Zhou
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

4.  High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.

Authors:  C-L Lin; S-L Tsai; T-H Lee; R-N Chien; S-K Liao; Y-F Liaw
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

Review 5.  Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.

Authors:  Steven-Huy B Han
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Drug treatment of pediatric chronic hepatitis B.

Authors:  Etienne Sokal
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

7.  Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive.

Authors:  Jung Woo Shin; Neung Hwa Park; Seok Won Jung; Byung Chul Kim; Sung Ho Kwon; Jae Serk Park; In Du Jeong; Sung-Jo Bang; Do Ha Kim
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

8.  Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus.

Authors:  Kang Mo Kim; Won-Beom Choi; Young-Suk Lim; Han-Chu Lee; Young-Hwa Chung; Young-Sang Lee; Dong-Jin Suh
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

9.  trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase.

Authors:  Richard A Heipertz; Jason L Starkey; Thomas G Miller; Jianming Hu; Harriet C Isom
Journal:  Virology       Date:  2009-04-19       Impact factor: 3.616

10.  Fatal outcome of SARS in a patient with reactivation of chronic hepatitis B.

Authors:  Alex Y Hui; Henry L Y Chan; Choong-Tsek Liew; Paul K S Chan; Ka-Fai To; Chin-Pang Chan; Joseph J Y Sung
Journal:  Am J Med       Date:  2003-09       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.